Annual Report 2024

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2024 87 The United Laboratories International Holdings Limited Annual Report 2024 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information (Continued) (b) Other segment information (Continued) For the year ended 31 December 2023 Intermediate Bulk Finished products medicine products Unallocated Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Amortisation of intangible assets 2,031 – 15,416 – 17,447 Depreciation of right-of-use assets 3,324 5,270 2,874 430 11,898 Depreciation of property, plant and equipment 388,205 87,827 60,198 73 536,303 Net loss on disposal of property, plant and equipment 1,603 1,151 949 – 3,703 Written off of property, plant and equipment 23,454 22,737 1,764 – 47,955 Write-down of inventories recognised 5,730 12,963 24,495 – 43,188 Impairment losses (reversed) recognised (1,216) (1,688) 1,494 (552) (1,962) (c) Geographical information The revenue by geographical market (irrespective of the origin of the goods) based on the location of the customers are presented below: Revenue from external customers 2024 2023 RMB’000 RMB’000 PRC, including Hong Kong (country of domicile) 11,115,585 11,124,265 Europe 695,589 783,732 India 634,347 673,922 Middle East 73,284 46,834 South America 363,284 340,391 Other Asian regions 633,318 603,726 Other regions 243,530 167,009 13,758,937 13,739,879